BPG is committed to discovery and dissemination of knowledge
Retrospective Study Open Access
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123857
Published online Nov 15, 2026. doi: 10.4251/wjgo.123857
Nab-paclitaxel-oxaliplatin-S-1 vs FOLFOX in locally advanced gastric cancer: Efficacy and postoperative disease-free survival prediction
Bao-Yan Ji, De-Yan Fan, Yun Zhang, Li He, Kuan Zhang, Zhi-Bo Liu, Department of Oncology, Qinghai Red Cross Hospital, Xining 810000, Qinghai Province, China
Lu-Lu Qi, Department of Otolaryngology, Qinghai University Affiliated Hospital, Xining 810000, Qinghai Province, China
ORCID number: Bao-Yan Ji (0009-0003-9766-8620); Lu-Lu Qi (0009-0002-5761-9675); De-Yan Fan (0009-0003-5090-127X); Yun Zhang (0009-0007-4160-263X); Li He (0009-0001-7756-1637); Kuan Zhang (0000-0001-5087-8346); Zhi-Bo Liu (0009-0002-7439-747X).
Co-first authors: Bao-Yan Ji and Lu-Lu Qi.
Co-corresponding authors: Kuan Zhang and Zhi-Bo Liu.
Author contributions: Ji BY and Qi LL contributed equally to this work, as they are co-first authors; Liu ZB and Zhang K supervised the project, they are co-corresponding authors; Ji BY and Qi LL performed the main experiments, analyzed the data, and drafted the manuscript; Fan DY, Zhang Y, and He L contributed to data collection, analysis, and manuscript revision; all authors reviewed and approved the final manuscript.
AI contribution statement: Since we are not native English speakers, after completing the writing in our native language, we used translation software to translate it. Additionally, we have sent the revised manuscript to a professional editing company for language refinement.
Supported by the Qinghai Red Cross Hospital Institutional Self-selected Research Project, No. YNZXKT2026023.
Institutional review board statement: This study approved by the Ethics Committee of the Affiliated Hospital of Qinghai University, No. P-SL-2022-035.
Informed consent statement: Written informed consent was obtained from all participants.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: The datasets used and/or analyzed during the current study are not publicly available due to privacy or ethical restrictions.
Corresponding author: Zhi-Bo Liu, MD, Professor, Department of Oncology, Qinghai Red Cross Hospital, No. 55 South Street, Chengzhong District, Xining 810000, Qinghai Province, China. liuzhibo0965@163.com
Received: June 3, 2026
Revised: June 17, 2026
Accepted: July 17, 2026
Published online: November 15, 2026
Processing time: 159 Days and 12 Hours

Abstract
BACKGROUND

Locally advanced gastric cancer remains associated with a considerable risk of recurrence despite perioperative chemotherapy and radical surgery. Folinic acid, fluorouracil, and oxaliplatin is widely used, whereas nab-paclitaxel, oxaliplatin, and S-1 has shown potential antitumor activity in clinical practice. However, real-world comparative evidence between these regimens and postoperative tools for individualized disease-free survival (DFS) prediction remain limited. We hypothesized that clinicopathological and treatment-response variables could support postoperative recurrence risk stratification.

AIM

To compare the short-term response, long-term outcomes, and safety of the FOLFOX and P-SOX regimens in patients with gastric cancer. Using clinicopathological data, treatment response, and follow-up information, we applied least absolute shrinkage and selection operator Cox regression to select key factors associated with DFS and constructed a nomogram for predicting DFS at 18 months, 24 months, and 36 months.

METHODS

This retrospective study included 181 patients with advanced gastric cancer who received preoperative and postoperative chemotherapy followed by standard D2 radical gastrectomy. Clinical data were collected from two centers: Qinghai University Affiliated Hospital and Qinghai Red Cross Hospital. Among these patients, 113 received the P-SOX regimen, and 68 received the FOLFOX regimen. In this real-world retrospective study, the choice between P-SOX and FOLFOX was based on physicians’ comprehensive assessment of patient condition, tumor status, treatment tolerance, economic factors, and patient preference rather than on random allocation. Patients were screened according to predefined inclusion and exclusion criteria, and the detailed eligibility criteria and treatment protocols are presented in the Supplementary material. Using the sample function in R, the cohort was randomly divided into a training set and a validation set at a 7:3 ratio for model development and internal validation, respectively. Short-term treatment response, long-term outcomes, and adverse events were compared between the two treatment groups. Clinical factors associated with DFS were further analyzed.

RESULTS

According to response evaluation criteria in solid tumors 1.1, the objective response rate was 61.1% in the P-SOX group and 51.5% in the FOLFOX group, with no statistically significant difference between the two groups (P = 0.206). Analysis based on tumor regression grade (TRG) revealed that the pathological response rate was 31.0% in the P-SOX group and 23.5% in the FOLFOX group, and the difference was not statistically significant (P = 0.281). For long-term outcomes, Kaplan-Meier survival analysis revealed that the DFS and overall survival (OS) curves of the P-SOX group were slightly greater than those of the FOLFOX group, but the differences were not statistically significant. The log-rank P value was 0.420 for DFS and 0.704 for OS. Adverse events were generally manageable in both groups and were mainly mild to moderate. No significant differences were detected between the FOLFOX and P-SOX groups in terms of nausea and vomiting, liver function impairment, alopecia, peripheral sensory neuropathy, neutropenia, thrombocytopenia, or anemia (all P > 0.05). The distribution of leukopenia differed significantly between the two groups (P = 0.027), with a higher proportion of grade 1 leukopenia in the P-SOX group, whereas grade 2 and grade 4 leukopenia were slightly more frequent in the FOLFOX group. Overall, the two regimens were comparable in terms of safety profiles, without an apparent increase in severe toxicity.

CONCLUSION

In summary, compared with the FOLFOX regimen, the P-SOX regimen tended to be favorable for short-term response and long-term survival outcomes, with numerically better OS and DFS. These findings suggest that P-SOX may represent a promising perioperative treatment option for patients with advanced gastric cancer. In addition, patients with a good perioperative treatment response, reflected by an improved TRG, a smaller tumor diameter (≤ 2 cm), an earlier clinical tumor node metastasis stage, and well-differentiated tumors, generally had better survival outcomes.

Key Words: Gastric cancer; FOLFOX; P-SOX; Disease-free survival; Nomogram

Core Tip: This retrospective two-center study compared FOLFOX and P-SOX regimens in patients with locally advanced gastric cancer undergoing perioperative chemotherapy and D2 radical gastrectomy. P-SOX showed numerically higher radiological and pathological response rates than FOLFOX, but the differences were not statistically significant. Survival curves also suggested a favorable trend for P-SOX without significant disease-free survival or overall survival improvement. A least absolute shrinkage and selection operator-Cox-based nomogram incorporating clinical tumor node metastasis stage, tumor regression grade response, and pre-chemotherapy tumor diameter was developed to predict 18-month, 24-month, and 36-month disease-free survival, providing a practical tool for postoperative recurrence risk stratification.



INTRODUCTION

Gastric cancer is one of the most common gastrointestinal malignancies in China, and a considerable proportion of patients are diagnosed at the locally advanced stage[1,2]. For these patients, surgery alone often fails to achieve satisfactory long-term survival. Perioperative chemotherapy combined with standard radical surgery has therefore become an important treatment strategy[3]. Neoadjuvant chemotherapy can reduce tumor size before surgery, achieve downstaging, increase the likelihood of R0 resection, and allow earlier control of potential micrometastatic disease. Postoperative adjuvant therapy may further reduce the risk of recurrence and improve long-term prognosis[4,5]. Evidence from international studies has shown that perioperative chemotherapy is widely used as part of comprehensive treatment for locally advanced gastric cancer. Combination regimens based on fluoropyrimidines and platinum agents are currently among the most commonly used options[6,7]. The FOLFOX regimen, which consists of oxaliplatin, fluorouracil, and leucovorin, has been used for many years and has accumulated substantial clinical experience in the treatment of gastrointestinal tumors. Some studies have also suggested that taxane-containing combination regimens may improve tumor regression, although adverse events such as myelosuppression, neurotoxicity, and alopecia should be carefully considered[8,9]. In recent years, perioperative treatment has gradually shifted from focusing solely on radiological response to a broader assessment that includes pathological regression, recurrence risk, and long-term survival. In China, a relatively high proportion of patients with gastric cancer present with locally advanced disease, and D2 radical gastrectomy combined with perioperative chemotherapy remains a major treatment strategy in clinical practice[10]. Oxaliplatin-containing regimens, such as SOX, CAPOX, and FOLFOX, are widely used and have shown a certain clinical basis in terms of efficacy and safety. The P-SOX regimen, which combines nab-paclitaxel with oxaliplatin and S-1, has also been increasingly used in recent years as neoadjuvant or perioperative treatment for advanced gastric cancer. Existing clinical observations suggest that P-SOX may have potential advantages in tumor response and pathological regression; however, differences in sample size, disease stage, treatment cycles, and response criteria across studies should be taken into account. Direct comparisons between FOLFOX and P-SOX regimens in real-world populations remain limited, particularly studies that simultaneously evaluate short-term efficacy, adverse events, and disease-free survival (DFS) prediction models. In addition to the treatment regimen itself, tumor stage, lymph node status, degree of differentiation, tumor size, and post-treatment response may all influence postoperative recurrence and survival outcomes[11,12]. Conventional univariate and multivariate regression analyses may be affected by multicollinearity and overfitting when a large number of variables are included. Least absolute shrinkage and selection operator (LASSO) regression can select variables with greater predictive value from multiple candidate factors and is therefore suitable for the development of clinical prognostic models. When combined with Cox regression and a nomogram, it can further estimate the probability of DFS at different time points, providing a reference for postoperative follow-up and individualized management. Based on this background, we retrospectively included patients with gastric cancer who received FOLFOX or P-SOX followed by surgical treatment. Baseline characteristics, short-term efficacy, and adverse events were compared between the two groups. With DFS as the primary outcome, LASSO-Cox regression was used to identify relevant predictors, and a nomogram was constructed to predict 18-month, 24-month, and 36-month DFS. This study aimed to provide clinical evidence for perioperative treatment selection and recurrence risk assessment in patients with gastric cancer.

MATERIALS AND METHODS
Assessments

Follow-up was conducted for up to 3 years after surgery. Patients were generally followed every 3 months during the first 2 years and every 6 months during the third year. Follow-up assessments included outpatient visits, inpatient medical records, telephone follow-up, serum tumor markers, abdominal and pelvic contrast-enhanced computed tomography, chest imaging, and gastroscopy when clinically indicated. Recurrence was defined as radiological or pathological evidence of locoregional relapse or distant metastasis. Patients without recurrence, metastasis, or death were censored at the date of the last follow-up.

Short-term efficacy assessment: Clinical response was evaluated according to the response evaluation criteria in solid tumors (RECIST 1.1). Complete response and partial response were classified as effective response, whereas stable disease and progressive disease were classified as ineffective response. Pathological response was assessed based on postoperative pathological findings and the National Comprehensive Cancer Network tumor regression grade (TRG) criteria. TRG grades 0-2 were defined as effective response, and TRG grade 3 was defined as ineffective response. Radiological measurements and pathological assessments were performed by experienced radiologists and pathologists, respectively. Short-term efficacy was finally compared among different chemotherapy regimens according to the RECIST 1.1 and TRG results.

Long-term efficacy assessment: Long-term efficacy was evaluated using DFS as the primary endpoint. DFS was defined as the time from radical surgery to the first occurrence of tumor recurrence, distant metastasis, death, or the last follow-up. Prognostic information was obtained through outpatient visits, inpatient medical records, imaging examinations, and telephone follow-up. Follow-up data mainly included tumor recurrence, metastasis, survival status, and the date of the most recent assessment. Patients without recurrence, metastasis, or death were censored at the time of the last follow-up. DFS was used to compare long-term outcomes between different chemotherapy regimens, and clinical factors associated with DFS were further analyzed.

Adverse event assessment: Adverse events were graded and recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.

Statistical analysis

All statistical analyses were performed using R software (version 4.6.0). Candidate variables were selected according to clinical relevance, availability in both centers, and completeness of medical records. The main model included variables that were consistently recorded during the study period, including age, sex, cT stage, cN stage, clinical tumor node metastasis (cTNM) stage, American Society of Anesthesiologists (ASA) score, tumor differentiation, pre-chemotherapy tumor diameter, tumor location, treatment regimen, RECIST 1.1 response, and TRG response. Nutritional indicators, Eastern Cooperative Oncology Group performance status, and molecular biomarkers such as human epidermal growth factor receptor 2 status, microsatellite instability/mismatch repair status, and programmed cell death ligand 1 combined positive score were not included in the primary model because these data were not uniformly available for all patients in this retrospective cohort. Including variables with substantial missingness may have reduced the effective sample size and introduced additional selection bias. Baseline characteristics were first compared between the two groups. Categorical variables are presented as n (%), and between-group comparisons were performed using the χ2 test or Fisher’s exact test, as appropriate. Chemotherapy-related adverse events were then analyzed as graded variables, and group differences were assessed using the χ2 test or Fisher’s exact test according to the data distribution. DFS was used as the primary outcome. Clinicopathological characteristics, short-term efficacy indicators, and treatment-related variables were included in the LASSO-Cox regression analysis. Ten-fold cross-validation was used to select the optimal penalty parameter λ, and candidate variables associated with DFS were identified. The selected variables were further evaluated using univariate Cox regression analysis. Variables with clinical relevance or statistical significance were then entered into a multivariate Cox regression model to determine independent factors associated with DFS. Based on the final multivariate Cox model, a nomogram was constructed to estimate the probability of DFS at 18 months, 24 months, and 36 months. Model discrimination was assessed using time-dependent receiver operating characteristic (ROC) curves and the area under the curve (AUC). Clinical benefit was evaluated by decision curve analysis (DCA), and agreement between predicted and observed outcomes was examined using calibration curves. All tests were two-sided, and P < 0.05 was considered statistically significant.

RESULTS

A total of 181 patients with gastric cancer were included in this study, as shown in Table 1. Among them, 68 patients received the FOLFOX regimen and 113 received the P-SOX regimen. No statistically significant differences were observed between the two groups in age, sex, cT stage, cN stage, clinical TNM stage, ASA score, degree of differentiation, pre-chemotherapy tumor diameter, or tumor location (all P > 0.05), indicating that the baseline characteristics were generally balanced and comparable between the two groups. Regarding short-term efficacy, RECIST 1.1 assessment showed an objective response rate of 61.1% in the P-SOX group, which was higher than the 51.5% observed in the FOLFOX group, although the difference was not statistically significant (P = 0.206). TRG evaluation showed a pathological response rate of 31.0% in the P-SOX group and 23.5% in the FOLFOX group, with no significant difference between the two groups (P = 0.281). Overall, the P-SOX group showed a favorable trend in radiological response and pathological regression, but its short-term efficacy was not significantly superior to that of the FOLFOX regimen.

Table 1 Basic patient characteristics and short-term efficacy, n (%).
Characteristic
Overall (n = 181)
FOLFOX (n = 68)
P-SOX (n = 113)
Statistic
P value1
Ageχ2 = 0.020.894
0100 (55.2)38 (55.9)62 (54.9)
181 (44.8)30 (44.1)51 (45.1)
Sexχ2 = 0.090.763
1151 (83.4)56 (82.4)95 (84.1)
230 (16.6)12 (17.6)18 (15.9)
cTχ2 = 0.280.868
240 (22.1)16 (23.5)24 (21.2)
392 (50.8)35 (51.5)57 (50.4)
449 (27.1)17 (25.0)32 (28.3)
cNχ2 = 0.050.825
055 (30.4)20 (29.4)35 (31.0)
1126 (69.6)48 (70.6)78 (69.0)
cTNMχ2 = 2.000.572
187 (48.1)37 (54.4)50 (44.2)
221 (11.6)6 (8.8)15 (13.3)
333 (18.2)11 (16.2)22 (19.5)
440 (22.1)14 (20.6)26 (23.0)
ASAχ2 = 0.390.530
0153 (84.5)56 (82.4)97 (85.8)
128 (15.5)12 (17.6)16 (14.2)
Differentiationχ2 = 0.280.871
150 (27.6)18 (26.5)32 (28.3)
253 (29.3)19 (27.9)34 (30.1)
378 (43.1)31 (45.6)47 (41.6)
RECIST 11χ2 = 1.600.206
077 (42.5)33 (48.5)44 (38.9)
1104 (57.5)35 (51.5)69 (61.1)
TRGχ2 = 1.160.281
051 (28.2)16 (23.5)35 (31.0)
1130 (71.8)52 (76.5)78 (69.0)
Tumor diameterχ2 = 4.570.102
173 (40.3)34 (50.0)39 (34.5)
268 (37.6)20 (29.4)48 (42.5)
340 (22.1)14 (20.6)26 (23.0)
Locationχ2 = 0.350.839
141 (22.7)14 (20.6)27 (23.9)
273 (40.3)29 (42.6)44 (38.9)
367 (37.0)25 (36.8)42 (37.2)

During treatment, adverse events in both groups were mostly mild to moderate, as shown in Table 2. No significant differences were observed between the FOLFOX and P-SOX groups in nausea and vomiting, liver function impairment, alopecia, peripheral sensory neuropathy, neutropenia, thrombocytopenia, or anemia (all P > 0.05). Leukopenia differed significantly between the two groups (P = 0.027), with grade 1 leukopenia being more frequent in the P-SOX group. Based on previous findings, this may be related to the use of a three-drug combination. However, leukopenia was generally manageable, and no leukocyte-raising agents were used during treatment. Overall, both regimens were well tolerated, and no obvious clustering of severe toxicities was observed in either treatment group.

Table 2 Side effects associated with two groups treatment, n (%).
Variables
Total (n = 181)
FOLFOX (n = 68)
P-SOX (n = 113)
Statistic
P value
Nausea and vomiting0.123
042 (23.20)13 (19.12)29 (25.66)
1101 (55.80)35 (51.47)66 (58.41)
234 (18.78)17 (25.00)17 (15.04)
34 (2.21)3 (4.41)1 (0.88)
Liver toxicity-0.165
0151 (83.43)58 (85.29)93 (82.30)
126 (14.36)7 (10.29)19 (16.81)
24 (2.21)3 (4.41)1 (0.88)
Alopeciaχ2 = 3.030.220
094 (51.93)36 (52.94)58 (51.33)
174 (40.88)30 (44.12)44 (38.94)
213 (7.18)2 (2.94)11 (9.73)
Peripheral sensory neuropathy0.790
091 (50.28)35 (51.47)56 (49.56)
172 (39.78)26 (38.24)46 (40.71)
216 (8.84)7 (10.29)9 (7.96)
32 (1.10)0 (0.00)2 (1.77)
Fewer neutrophils0.387
0132 (72.93)45 (66.18)87 (76.99)
134 (18.78)16 (23.53)18 (15.93)
27 (3.87)4 (5.88)3 (2.65)
37 (3.87)3 (4.41)4 (3.54)
41 (0.55)0 (0.00)1 (0.88)
Fewer white blood cells0.027
0102 (56.35)43 (63.24)59 (52.21)
154 (29.83)14 (20.59)40 (35.40)
216 (8.84)8 (11.76)8 (7.08)
35 (2.76)0 (0.00)5 (4.42)
44 (2.21)3 (4.41)1 (0.88)
Fewer platelets0.521
0133 (73.48)52 (76.47)81 (71.68)
131 (17.13)10 (14.71)21 (18.58)
212 (6.63)3 (4.41)9 (7.96)
35 (2.76)3 (4.41)2 (1.77)
Anemiaχ2 = 2.640.450
094 (51.93)36 (52.94)58 (51.33)
162 (34.25)21 (30.88)41 (36.28)
215 (8.29)5 (7.35)10 (8.85)
310 (5.52)6 (8.82)4 (3.54)
Efficacy

In terms of short-term efficacy, treatment response was evaluated using both RECIST 1.1 and TRG. RECIST 1.1 mainly reflects changes in measurable tumor lesions on imaging before and after treatment. In the FOLFOX group, 35 patients achieved an imaging response, accounting for 51.5%, whereas 33 patients were classified as non-responders, accounting for 48.5%. In the P-SOX group, 69 patients achieved an imaging response, accounting for 61.1%, and 44 patients were classified as non-responders, accounting for 38.9%. Numerically, the RECIST 1.1 response rate was higher in the P-SOX group than in the FOLFOX group, suggesting that P-SOX may have a potential advantage in radiological tumor response. However, the difference between the two groups was not statistically significant (χ2 = 1.60, P = 0.206). Therefore, the current results do not support a significant superiority of P-SOX over FOLFOX in terms of radiological short-term efficacy. TRG mainly reflects pathological tumor regression after surgery and provides further information on the histological response to neoadjuvant or perioperative treatment. As shown in Table 1, 16 patients in the FOLFOX group achieved an effective pathological response, accounting for 23.5%, whereas 52 patients were classified as ineffective, accounting for 76.5%. In the P-SOX group, 35 patients achieved an effective pathological response, accounting for 31.0%, and 78 patients were classified as ineffective, accounting for 69.0%. The TRG response rate was also numerically higher in the P-SOX group, indicating a favorable trend in pathological regression. However, this difference was not statistically significant (χ2 = 1.16, P = 0.281), suggesting that the two regimens had broadly comparable pathological short-term efficacy. Taken together, the P-SOX group showed higher radiological response and pathological regression rates than the FOLFOX group, but neither comparison reached statistical significance.

In terms of long-term outcomes, DFS and overall survival (OS) were compared between the FOLFOX and P-SOX groups using the Kaplan-Meier method. The DFS curves (Figure 1A) were generally similar between the two groups. During the early follow-up period, the DFS curve for the P-SOX group was slightly higher than that for the FOLFOX group. In the middle and later stages of follow-up, the two curves gradually became closer, although the P-SOX group still showed a modest favorable trend. The risk table showed that, at 30 months of follow-up, 21 patients remained at risk in the FOLFOX group, with 47 cumulative events, while 37 patients remained at risk in the P-SOX group, with 77 cumulative events. The log-rank test showed no significant difference in DFS between the two groups (P = 0.420), indicating that P-SOX did not provide a statistically significant DFS benefit over FOLFOX. For OS (Figure 1B), the OS curves were also close between the two groups. The P-SOX group showed a slightly higher survival curve during the early follow-up period, but the curves gradually overlapped over time, with no clear difference in the later period. At 30 months of follow-up, 29 patients remained at risk in the FOLFOX group, with 42 cumulative deaths, while 53 patients remained at risk in the P-SOX group, with 65 cumulative deaths. The log-rank test showed no statistically significant difference in OS between the two groups (P = 0.704).

Figure 1
Figure 1 Comparison of disease-free survival and overall survival between the FOLFOX and P-SOX groups. A: Disease-free survival; B: Overall survival. DFS: Disease-free survival; OS: Overall survival.
Variable selection by LASSO regression

The results of the LASSO-Cox regression analysis are shown in Figure 2. Figure 2A presents the 10-fold cross-validation curve. The X-axis represents log(λ), and the Y-axis represents the partial likelihood deviance. As λ changed, the model error first decreased and then increased, suggesting that an appropriate penalty parameter could reduce model overfitting. The two vertical dashed lines indicate the λ value corresponding to the minimum cross-validation error and the λ value within one standard error, respectively. After selecting the optimal λ value based on cross-validation, some variable coefficients were shrunk to zero, and variables with non-zero coefficients were retained for subsequent model analysis. Figure 2B shows the coefficient profiles of the candidate variables in the LASSO model. As λ increased, the coefficients of the variables gradually shrank toward zero, with each curve representing a different clinical variable. The dashed vertical line indicates the finally selected λ value. Variables that retained non-zero coefficients at this λ value were considered to be more closely associated with DFS. Figure 2C further illustrates the magnitude and direction of the coefficients of the retained variables. Positive coefficients were observed for cTNM stage IIIC, cTNM stage IIIB, tumor diameter > 5 cm, poor differentiation, positive lymph node metastasis, and clinical T4 stage. Among these variables, cTNM stage IIIC had the largest coefficient, suggesting that advanced clinical stage contributed most strongly to unfavorable DFS outcomes. In contrast, effective TRG response and effective RECIST 1.1 response had negative coefficients, indicating a relatively lower risk of DFS events in patients with better treatment response. Tumor diameter of 2-5 cm, moderate differentiation, and cTNM stage IIIA had coefficients close to zero, suggesting a relatively limited contribution to the model.

Figure 2
Figure 2 Least absolute shrinkage and selection operator regression analysis. A: Least absolute shrinkage and selection operator (LASSO) regression with 10-fold cross-validation for selection of the optimal penalty parameter; B: LASSO coefficient profiles of candidate variables as a function of log(λ); C: Coefficients of variables retained by the LASSO-Cox regression model. cTNM: Clinical tumor node metastasis; RECIST: Response evaluation criteria in solid tumors; TRG: Tumor regression grade.
Cox regression analysis

Multivariate Cox regression analysis showed that cTNM stage, TRG response, and pre-chemotherapy tumor diameter were the main factors associated with DFS (Table 3). Compared with patients with cTNM stage 1, those with cTNM stage 3 and stage 4 had a significantly higher risk of DFS events, with hazard ratio (HRs) of 3.30 [95% confidence interval (CI): 1.70-6.39, P < 0.001] and 5.42 (95%CI: 2.34-12.54, P < 0.001), respectively. Patients with an effective TRG response had a lower risk of DFS events than those with an ineffective TRG response (HR = 0.51, 95%CI: 0.31-0.83, P = 0.007). Patients in tumor diameter group 3 also showed a significantly increased risk of DFS events (HR = 2.93, 95%CI: 1.55-5.55, P < 0.001). In contrast, cT stage, cN status, tumor differentiation, and RECIST 1.1 response did not reach statistical significance in the multivariate analysis.

Table 3 Results of multivariate Cox proportional hazards regression analyses.
Characteristic
n
Event n
HR
95%CI
P value
cT
22919
367440.880.45-1.700.694
431251.170.49-2.790.721
cN
04024
187641.460.86-2.490.166
cTNM
15726
216111.780.83-3.810.141
328273.301.70-6.39< 0.001
426245.422.34-12.54< 0.001
Differentiation
13619
237210.940.49-1.810.863
354481.310.73-2.330.363
RECIST 11
05343
174450.670.42-1.080.098
TRG
03531
192570.510.31-0.830.007
Tumor diameter
15130
250351.380.82-2.350.228
326232.931.55-5.55< 0.001
Development of a nomogram for DFS

Based on the multivariate Cox regression results, a nomogram was further developed to predict 18-month, 24-month, and 36-month DFS in patients with gastric cancer (Figure 3). The final model included three variables: Clinical TNM stage, TRG, and pre-chemotherapy tumor diameter. In the nomogram, each variable was assigned a score according to its relative contribution to DFS.

Figure 3
Figure 3 Disease-free survival nomogram. cTNM: Clinical tumor node metastasis; DFS: Disease-free survival; TRG: Tumor regression grade.

Clinical TNM stage contributed the largest proportion of the total score. Stage IIIC corresponded to approximately 100 points, stage IIIB to approximately 64 points, stage IIIA to approximately 33 points, and stage IIB to nearly 0 points, indicating that more advanced clinical stage was associated with a higher risk of DFS events. For TRG, patients with an ineffective pathological regression response were assigned a higher score of approximately 33 points, whereas those with an effective response had a score close to 0, suggesting that better pathological regression was associated with a lower risk of recurrence. Pre-chemotherapy tumor diameter was also included in the model. A tumor diameter > 5 cm corresponded to approximately 41 points, a diameter of 2-5 cm corresponded to a lower score, and a diameter ≤ 2 cm was close to 0 points, indicating that a larger tumor burden was related to poorer DFS. When using the nomogram, points are assigned according to the patient’s cTNM stage, TRG result, and pre-chemotherapy tumor diameter, and the three scores are summed to obtain the total score. A higher total score corresponds to a higher linear predictor and a lower predicted probability of DFS at 18 months, 24 months, and 36 months. As shown in the figure, the predicted DFS probability gradually decreased as the total score increased. This model integrates clinical stage, pathological regression response, and tumor burden into a single scoring system, which may help stratify postoperative recurrence risk and guide follow-up management.

Model validation

Time-dependent ROC curves were used to evaluate the ability of the nomogram to predict DFS at 18 months, 24 months, and 36 months (Figure 4). The X-axis represents 1-specificity, and the Y-axis represents sensitivity. The black dashed line indicates the reference line with no predictive value. A ROC curve closer to the upper-left corner indicates better discrimination for recurrence risk. In the training set, the model showed good discrimination for DFS at different time points. The AUC was 0.815 for 18-month DFS (95%CI: 0.724-0.906), 0.796 for 24-month DFS (95%CI: 0.717-0.874), and 0.835 for 36-month DFS (95%CI: 0.734-0.935). All three curves were clearly above the reference line, suggesting stable predictive performance in the training set, with the highest AUC observed for 36-month DFS. In the validation set, the model retained a certain level of predictive ability. The AUC was 0.830 for 18-month DFS (95%CI: 0.674-0.987), 0.648 for 24-month DFS (95%CI: 0.498-0.798), and 0.767 for 36-month DFS (95%CI: 0.586-0.949). The model performed better in predicting 18-month and 36-month DFS, whereas its performance for 24-month DFS was relatively lower, which may be related to the limited sample size and number of events in the validation set. The lower AUC for 24-month DFS in the validation set indicates that the predictive performance of the nomogram was not completely stable across all time points. Therefore, the 24-month prediction should be interpreted with caution. The model appeared to perform better for 18-month and 36-month DFS, whereas its reliability at the intermediate 24-month time point requires further confirmation in larger external cohorts.

Figure 4
Figure 4 Disease-free survival receiver operating characteristic curve. A: 18 months, 24 months, 36 months training set; B: 18 months, 24 months, 36 months validation set. AUC: Area under the curve; CI: Confidence interval.

DCA was used to assess the clinical utility of the nomogram across different threshold probabilities (Figure 5). In the figure, the red line represents the “treat-all” strategy, the green line represents the “treat-none” strategy, and the blue line represents the model-based prediction strategy. A higher net benefit indicates greater clinical value for decision-making. In the training set, the model showed favorable net benefit for predicting DFS at 18 months, 24 months, and 36 months. For 18-month DFS, the DCA curve showed that the model provided a positive net benefit across a relatively wide range of threshold probabilities. The model curve was generally above the “treat-none” line and was higher than the “treat-all” line over most threshold ranges, suggesting potential clinical benefit for assessing 18-month DFS risk. For 24-month DFS, the model maintained a relatively high net benefit within the low-to-moderate threshold probability range and performed better than either the “treat-all” or “treat-none” strategy alone. For 36-month DFS, the model curve was positioned higher overall and remained above both reference lines across most threshold probabilities, indicating good decision-making value for longer-term DFS risk assessment. In the validation set, the model also showed a certain degree of clinical applicability. The DCA curve for 18-month DFS showed a positive net benefit across most threshold probability ranges, suggesting relatively stable performance in validation. For 24-month DFS, the net benefit was weaker, and the model curve declined in some medium-to-high threshold ranges, indicating limited predictive value at this time point. This may be related to the small sample size and limited number of events in the validation set. For 36-month DFS, the model still provided a favorable net benefit within the low-to-moderate threshold probability range, although the benefit gradually decreased at higher threshold probabilities.

Figure 5
Figure 5 Decision curve analysis of the nomogram for predicting disease-free survival. A: 18-month training set; B: 24-month training set; C: 36-month training set; D: 18-month validation set; E: 24-month validation set; F: 36-month validation set.

Calibration curves were used to assess the agreement between the risks predicted by the nomogram and the observed outcomes, as shown in Figure 6. The gray diagonal line represents perfect prediction, whereas the black curve represents the model prediction. In the training set, the calibration curves for 18-month, 24-month, and 36-month DFS were generally close to the ideal line, indicating good agreement between the predicted probabilities and the actual outcomes. For 18-month DFS, the AUC was 81.7% (95%CI: 72.8%-90.6%), and the Brier score was 14.1% (95%CI: 10.6%-17.6%). For 24-month DFS, the AUC was 79.0% (95%CI: 71.2%-86.8%), with a Brier score of 18.6% (95%CI: 14.7%-22.4%). For 36-month DFS, the AUC was 83.5% (95%CI: 73.4%-93.5%), and the Brier score was 15.0% (95%CI: 10.0%-20.0%). In the validation set, the calibration curves for 18-month and 36-month DFS remained reasonably close to the ideal line, suggesting acceptable predictive agreement in the validation cohort. For 18-month DFS, the AUC was 76.7% (95%CI: 60.4%-93.0%), and the Brier score was 15.2% (95%CI: 8.7%-21.7%). For 36-month DFS, the AUC was 76.7% (95%CI: 58.6%-94.9%), with a Brier score of 17.9% (95%CI: 10.6%-25.3%). By contrast, the calibration performance for 24-month DFS was relatively weaker, with an AUC of 65.8% (95%CI: 51.3%-80.3%) and a Brier score of 26.0% (95%CI: 18.7%-33.3%). This finding suggests limited predictive stability at this time point, possibly due to the small sample size and limited number of events in the validation set.

Figure 6
Figure 6 Calibration curves of the nomogram for predicting disease-free survival. A: 18-month training set; B: 24-month training set; C: 36-month training set; D: 18-month validation set; E: 24-month validation set; F: 36-month validation set. AUC: Area under the curve.
DISCUSSION

This study evaluated the short-term efficacy, long-term survival, safety, and DFS prediction model of two perioperative chemotherapy regimens, FOLFOX and P-SOX, in patients with locally advanced gastric cancer. Compared with the FOLFOX group, the P-SOX group had higher RECIST 1.1 radiological response and TRG pathological response rates, although the differences were not statistically significant. According to the results of the Kaplan-Meier survival analysis, the DFS and OS curves of the P-SOX group were slightly greater than those of the FOLFOX group, but the log-rank tests did not reveal significant differences. In terms of safety, most adverse events were comparable between the two groups, with only leukopenia showing a significant difference in distribution. Further model development revealed that cTNM stage, TRG, and prechemotherapy tumor diameter were important factors associated with DFS and were included in the nomogram for predicting 18-month, 24-month, and 36-month DFS. The model showed acceptable discrimination and calibration in both the training and validation sets, suggesting that it may serve as an auxiliary tool for postoperative recurrence risk assessment.

The lower predictive performance for 24-month DFS in the validation set deserves further consideration. In the present study, the validation cohort was relatively small, and the number of events available for time-dependent ROC estimation at a fixed intermediate time point was limited. Unlike 18-month DFS, which reflects mainly early postoperative recurrence, and 36-month DFS, which captures more cumulative recurrence events, 24-month DFS may represent a transition period with greater heterogeneity in recurrence risk. In addition, random splitting of a modest cohort may lead to an uneven distribution of events and censored cases around this time point. These factors may explain the reduced 24-month AUC in the validation set. Future studies may improve the robustness of the model by using larger external validation cohorts, bootstrap resampling, repeated cross-validation, and, when appropriate, pooled or dynamic time-point prediction methods. The value of perioperative treatment for locally advanced gastric cancer has been confirmed by several international studies. The MAGIC trial, one of the earlier studies to establish the role of perioperative chemotherapy in resectable gastric cancer, revealed that preoperative plus postoperative chemotherapy could improve long-term outcomes in surgical patients[13,14]. The FLOT4 study further promoted the use of taxane-containing triplet regimens in Western countries, with FLOT achieving better pathological response and survival benefits than conventional ECF/ECX regimens. In Asian populations, the CLASSIC trial supported the use of oxaliplatin-containing adjuvant chemotherapy after D2 gastrectomy, while the RESOLVE trial also suggested that SOX-based perioperative treatment strategies may have good clinical value in locally advanced gastric cancer[15-17]. Taken together, these studies indicate that surgery alone is no longer sufficient for many patients with locally advanced gastric cancer. Comprehensive treatment strategies based on fluoropyrimidines, platinum agents, and taxanes remain important for improving tumor regression and reducing recurrence risk. In the present study, the RECIST 1.1 response rate was 61.1% in the P-SOX group, which was higher than the 51.5% observed in the FOLFOX group. With respect to the pathological response based on TRG, the response rate was 31.0% in the P-SOX group and 23.5% in the FOLFOX group. Although neither comparison was statistically significant, the direction of the results was consistent, suggesting that P-SOX may have a potential advantage in terms of short-term efficacy. The lack of statistically significant differences between the two groups should not be interpreted as evidence of therapeutic equivalence. The size of the FOLFOX group was smaller than that of the P-SOX group, and the overall sample size was modest. Therefore, the study may have been underpowered to detect moderate differences in response or survival outcomes. The numerically greater response rates and survival curves observed in the P-SOX group should be regarded as exploratory and hypothesis-generating rather than as confirmatory evidence of clinical benefit. These findings are generally in line with the view from international studies that intensified perioperative chemotherapy may improve the degree of tumor regression. The P-SOX regimen consists of nab-paclitaxel, oxaliplatin, and S-1, combining the antitumor effects of a taxane, a platinum agent, and a fluoropyrimidine. Taxanes inhibit microtubule depolymerization and enhance tumor cell cycle arrest; oxaliplatin induces DNA cross-linking damage, and S-1 has been widely used in Asian patients with gastric cancer, with relatively favorable tolerability. The three-drug combination may increase the cytotoxic intensity against tumor cells and may also contribute to a more evident trend toward pathological regression[18,19]. The lack of statistically significant differences in this study may be related to the limited sample size, unequal group distribution, differences in treatment cycles, and variability in pathological response assessment. In real-world settings, patients’ baseline conditions and treatment adjustments are often more complex, which may dilute differences in efficacy between the treatment regimens. RECIST 1.1 and TRG do not reflect exactly the same aspects of treatment response. RECIST depends mainly on changes in the size of radiologically measurable lesions and is suitable for evaluating tumor shrinkage. After neoadjuvant treatment for gastric cancer, fibrosis, necrosis, inflammatory changes, and scar-like tissue may occur, and changes in tumor volume may not always accurately reflect the number of residual tumor cells. By contrast, TRG is based on postoperative pathological findings and is more closely related to the histological tumor response. Previous international studies have generally suggested that the degree of pathological regression is closely associated with recurrence risk and survival outcomes. Studies such as FLOT4 have also used pathological response as an important indicator for evaluating intensified perioperative treatment[20]. In the present study, the P-SOX group had higher response rates at both the RECIST and TRG levels, suggesting that the potential advantage of this regimen was not simply due to radiological measurement bias. Multivariate Cox regression further revealed that patients with an effective TRG response had a lower risk of adverse DFS events, with an HR of 0.51 and a P value of 0.007. These findings support the prognostic value of the TRG in locally advanced gastric cancer and suggest that postoperative pathological response may serve as an important link between short-term efficacy and long-term outcomes.

In terms of long-term survival, the DFS and OS curves of the P-SOX group were slightly greater than those of the FOLFOX group, but the log-rank P values for DFS and OS were 0.420 and 0.704, respectively, and neither was statistically significant. These results should be interpreted with caution. In large international studies, the survival benefits of perioperative chemotherapy usually require larger sample sizes and longer follow-up to be clearly demonstrated. Studies such as MAGIC, FLOT4, CLASSIC, and RESOLVE were based on relatively large cohorts and standardized follow-up, which allowed the effects of treatment regimens on survival outcomes to be more clearly observed[21,22]. In this study, only 181 patients were included, and the numbers of patients in the two groups were not completely balanced. The number of events and the length of follow-up may have limited the ability to detect survival differences. The slight upward shift of the P-SOX curve may indicate a possible favorable trend, but it should not be regarded as direct evidence of therapeutic superiority. A more appropriate interpretation is that P-SOX showed a potential benefit signal in this cohort, which still requires confirmation in multicenter, large-sample, prospective studies. Safety is an important prerequisite for the wider use of perioperative treatment. In international studies, intensified chemotherapy has often been associated with increased rates of myelosuppression, gastrointestinal reactions, neurotoxicity, and alopecia. Taxane-containing regimens, in particular, may be more likely to cause alopecia and hematological toxicity[23].

FLOT-like regimens have shown favorable efficacy, but they also require better patient performance status and more intensive treatment management. As P-SOX is also a relatively intensified triplet regimen, its safety profile deserves particular attention. In the present study, no significant differences were observed between the two groups in terms of nausea and vomiting, liver function impairment, alopecia, peripheral sensory neuropathy, neutropenia, thrombocytopenia, or anemia. Leukopenia differed significantly between the two groups. Grade 1 leukopenia was more frequent in the P-SOX group, whereas higher-grade leukopenia was slightly more common in the FOLFOX group. Overall, P-SOX was not associated with an obvious increase in severe toxicity, suggesting that this regimen has acceptable tolerability in patients who underwent standard D2 radical gastrectomy and achieved R0 resection. These findings are generally consistent with previous safety reports on oxaliplatin- and taxane-containing perioperative regimens, in which intensified treatment may increase hematological toxicity, but most events can be controlled through careful monitoring, dose adjustment, and supportive care[24].

Multivariate Cox regression showed that cTNM stage was one of the strongest factors associated with DFS. Compared with patients with stage IIB disease, those with stage IIIB and IIIC disease had a significantly higher risk of adverse DFS events, with the highest risk observed in stage IIIC patients. These findings are highly consistent with those of previous gastric cancer studies. TNM stage integrates the depth of primary tumor invasion and the lymph node metastatic burden and remains the core indicator for prognostic stratification in gastric cancer. A more advanced disease even after perioperative chemotherapy and R0 resection indicates a higher risk of micrometastasis and recurrence. FLOT4, CLASSIC, and several Asian cohort studies have shown that advanced disease is associated with increased risks of recurrence and death[25]. In the present cohort, cTNM stage remained important for both LASSO Cox selection and multivariate analysis, supporting its stable predictive value. For patients with stage IIIB or IIIC disease, closer postoperative follow-up, more frequent imaging assessments, and stricter management of adjuvant treatment may be warranted.

Pre-chemotherapy tumor diameter was also an important factor associated with DFS in this study. Patients with a tumor diameter > 5 cm had a significantly higher risk of adverse DFS events, with an HR of 2.93 and a P value < 0.001. Tumor diameter reflects local tumor burden and may also be related to the extent of invasion, lymph node metastasis, a hypoxic tumor microenvironment, and chemotherapy sensitivity. Although tumor size is not a core component of TNM staging, it has often been used in international studies to predict pathological response, surgical difficulty, and postoperative recurrence risk. Larger tumors usually have greater heterogeneity, more internal necrosis and poorly perfused regions, which may reduce effective drug exposure and increase the risk of residual disease after treatment. By including tumor diameter in the nomogram, the model considers not only tumor stage but also a quantifiable indicator of tumor burden, which may improve its clinical applicability.

In this study, TRG was included in the final model, whereas RECIST 1.1 did not reach statistical significance. This suggests that postoperative pathological response may be more closely related to DFS than radiological response. This finding is also in line with current trends in international studies. In recent years, perioperative gastric cancer research has increasingly emphasized pathological complete response, major pathological response, and TRG classification, rather than relying solely on RECIST-based assessment[26,27].

In addition, this study used LASSO-Cox regression for variable selection and established a nomogram to predict 18-month, 24-month, and 36-month DFS. The LASSO method can shrink unstable coefficients among multiple candidate variables and reduce the risk of overfitting, making it suitable for clinical prediction studies with a limited sample size and multiple variables. The final model included cTNM stage, TRG, and pre-chemotherapy tumor diameter, which represent tumor stage, treatment response, and tumor burden, respectively. These variables have clear clinical relevance. The AUCs for predicting 18-month, 24-month, and 36-month DFS were 0.815, 0.796, and 0.835 in the training set, and 0.830, 0.648, and 0.767 in the validation set, respectively. Overall, the model performed better for predicting 18-month and 36-month DFS, whereas its performance for 24-month DFS in the validation set was relatively weak. The calibration curves showed that the predicted risks were generally close to the observed risks, and DCA suggested a positive net benefit within certain threshold ranges. These findings indicate that the model has not only statistical discriminative ability, but also potential value for clinical decision-making. The reduced predictive performance at 24 months may be related to the sample size of the validation set, event distribution, and censoring proportion. Further validation in external cohorts is still needed. From a clinical perspective, this nomogram is more suitable as a postoperative risk stratification tool rather than a tool used solely for preoperative treatment selection, because TRG is a postoperative pathological variable and cannot be obtained before treatment. The main value of the model lies in reassessing recurrence risk after completion of perioperative treatment and R0 resection. Patients with more advanced cTNM stage, ineffective TRG response, and tumor diameter > 5 cm usually receive higher risk scores in the model. These patients may require closer follow-up, with more intensive imaging examinations and tumor marker monitoring when necessary. In contrast, patients with earlier-stage disease, favorable pathological response, and smaller tumors may have a relatively lower risk of recurrence, allowing unnecessary examinations to be reduced under standard follow-up protocols. Although the model cannot replace clinical judgment, it may help clinicians integrate tumor stage, pathological response, and tumor burden into a unified framework and make risk communication more intuitive.

Limitations

Several limitations should be acknowledged in this study. First, this was a retrospective study, and the choice of treatment regimen may have been influenced by patients’ general condition, physician preference, economic factors, and drug availability. Therefore, selection bias could not be completely avoided. Second, the sample size was limited, and the number of patients in the FOLFOX group was smaller than that in the P-SOX group. Some differences in outcomes may not have reached statistical significance because of insufficient statistical power. Third, although the cohort was divided into a training set and a validation set, the validation remained internal, and an independent external cohort was not available. Fourth, the model included postoperative variables such as TRG; therefore, it is more appropriate for post-treatment prognostic assessment and should not be interpreted as a pretreatment decision-making model. Fifth, the follow-up duration and number of events may still have affected the stability of DFS prediction. Future multicenter prospective studies with larger sample sizes are needed. External validation should also be performed. In addition, molecular subtypes, inflammatory markers, nutritional status, and radiomics features may be incorporated in future models to further improve predictive performance. Because this was a retrospective real-world study, treatment allocation was based on clinical judgment rather than random assignment. Although the baseline characteristics were generally comparable, potential confounding by indication could not be fully excluded. The absence of propensity score adjustment may limit the causal interpretation of survival comparisons, and future larger studies with propensity score methods are needed to validate these findings. In addition, the modest and uneven sample size may have limited statistical power; therefore, the non-significant findings should not be interpreted as equivalence and require validation in larger cohorts. Multiple comparisons were performed for treatment response and adverse events, but no formal correction was applied. Therefore, isolated P values, particularly the nominal difference in leukopenia, should be interpreted cautiously.

CONCLUSION

In summary, the P-SOX regimen showed a favorable trend in short-term response and long-term survival outcomes, with numerically better OS and DFS than the FOLFOX regimen. These findings suggest that P-SOX may represent a promising perioperative treatment option for patients with advanced gastric cancer. In addition, patients with a good perioperative treatment response, reflected by improved TRG, smaller tumor diameter (≤ 2 cm), earlier cTNM stage, and well-differentiated tumors generally showed better survival outcomes.

References
1.  Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4:47-53.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1395]  [Cited by in RCA: 1759]  [Article Influence: 879.5]  [Reference Citation Analysis (10)]
2.  Xie X, Su J, Wang W, Wei H, Zhou Q, Su Y, Zhang L. Trends in Stomach Cancer Burden in China: A Joinpoint and APC Analysis Based on GBD 2021. J Gastroenterol Hepatol. 2025;40:1500-1514.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 5]  [Reference Citation Analysis (0)]
3.  Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115-132.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 11304]  [Cited by in RCA: 13271]  [Article Influence: 1327.1]  [Reference Citation Analysis (18)]
4.  Miao ZF, Liu XY, Wang ZN, Zhao TT, Xu YY, Song YX, Huang JY, Xu H, Xu HM. Effect of neoadjuvant chemotherapy in patients with gastric cancer: a PRISMA-compliant systematic review and meta-analysis. BMC Cancer. 2018;18:118.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 41]  [Cited by in RCA: 47]  [Article Influence: 5.9]  [Reference Citation Analysis (1)]
5.  GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group; Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E, Buyse M. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729-1737.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 633]  [Cited by in RCA: 607]  [Article Influence: 37.9]  [Reference Citation Analysis (9)]
6.  Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A, Smyth EC; ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005-1020.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1159]  [Cited by in RCA: 1165]  [Article Influence: 291.3]  [Reference Citation Analysis (19)]
7.  Yıldız İ, Özer L, Şenocak Taşçı E, Bayoglu İV, Aytac E. Current trends in perioperative treatment of resectable gastric cancer. World J Gastrointest Surg. 2023;15:323-337.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in CrossRef: 1]  [Cited by in RCA: 6]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
8.  Jiang Z, Xie Y, Zhang W, Du C, Zhong Y, Zhu Y, Jiang L, Dou L, Shao K, Sun Y, Xue Q, Tian Y, Gao S, Zhao D, Zhou A. Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial. Gastric Cancer. 2024;27:571-579.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 13]  [Cited by in RCA: 16]  [Article Influence: 8.0]  [Reference Citation Analysis (2)]
9.  Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-4997.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1526]  [Cited by in RCA: 1413]  [Article Influence: 70.7]  [Reference Citation Analysis (14)]
10.  Achilli P, De Martini P, Ceresoli M, Mari GM, Costanzi A, Maggioni D, Pugliese R, Ferrari G. Tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma: a prospective, multi-center cohort study. J Gastrointest Oncol. 2017;8:1018-1025.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 47]  [Cited by in RCA: 45]  [Article Influence: 5.0]  [Reference Citation Analysis (7)]
11.  el Aziz LM. Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4. Med Oncol. 2014;31:311.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 17]  [Cited by in RCA: 20]  [Article Influence: 1.7]  [Reference Citation Analysis (2)]
12.  Wang FY, Huang XM, Cao YQ, Cao J, Song M, Fang ZJ, Huang XE. Comparison of PSOX (paclitaxel, oxaliplatin, S-1) and SOX (oxaliplatin, S-1) as postoperative adjuvant chemotherapy for stage II-III gastric cancer. World J Surg Oncol. 2025;23:75.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 8]  [Reference Citation Analysis (2)]
13.  Bringeland EA, Wasmuth HH, Grønbech JE. Perioperative chemotherapy for resectable gastric cancer - what is the evidence? Scand J Gastroenterol. 2017;52:647-653.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 8]  [Cited by in RCA: 12]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
14.  Chuang J, Gong J, Klempner SJ, Woo Y, Chao J. Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. J Gastrointest Oncol. 2018;9:560-572.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 8]  [Cited by in RCA: 12]  [Article Influence: 1.5]  [Reference Citation Analysis (1)]
15.  Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17:1697-1708.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 611]  [Cited by in RCA: 566]  [Article Influence: 56.6]  [Reference Citation Analysis (8)]
16.  Lavacchi D, Fancelli S, Buttitta E, Vannini G, Guidolin A, Winchler C, Caliman E, Vannini A, Giommoni E, Brugia M, Cianchi F, Pillozzi S, Roviello G, Antonuzzo L. Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing. Int J Mol Sci. 2023;24:4877.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 10]  [Cited by in RCA: 14]  [Article Influence: 4.7]  [Reference Citation Analysis (0)]
17.  Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315-321.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1359]  [Cited by in RCA: 1370]  [Article Influence: 97.9]  [Reference Citation Analysis (32)]
18.  Kurokawa Y, Kawase T, Takeno A, Furukawa H, Yoshioka R, Saito T, Takahashi T, Shimokawa T, Eguchi H, Doki Y. Phase 2 trial of neoadjuvant docetaxel, oxaliplatin, and S-1 for clinical stage III gastric or esophagogastric junction adenocarcinoma. Ann Gastroenterol Surg. 2023;7:247-254.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 12]  [Cited by in RCA: 21]  [Article Influence: 7.0]  [Reference Citation Analysis (5)]
19.  Maehara Y. S-1 in gastric cancer: a comprehensive review. Gastric Cancer. 2003;6 Suppl 1:2-8.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 73]  [Cited by in RCA: 73]  [Article Influence: 3.2]  [Reference Citation Analysis (1)]
20.  Tomasello G, Petrelli F, Ghidini M, Pezzica E, Passalacqua R, Steccanella F, Turati L, Sgroi G, Barni S. Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies. Eur J Surg Oncol. 2017;43:1607-1616.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 62]  [Cited by in RCA: 106]  [Article Influence: 11.8]  [Reference Citation Analysis (0)]
21.  Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 5161]  [Cited by in RCA: 4754]  [Article Influence: 237.7]  [Reference Citation Analysis (28)]
22.  Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948-1957.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 2158]  [Cited by in RCA: 2037]  [Article Influence: 291.0]  [Reference Citation Analysis (23)]
23.  Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Park YS, Son T, Jung MR, Heo MH, Kim HK, Park C, Yoo CH, Choi JH, Zang DY, Jang YJ, Sul JY, Kim JG, Kim BS, Beom SH, Cho SH, Ryu SW, Kook MC, Ryoo BY, Kim HK, Yoo MW, Lee NS, Lee SH, Kim G, Lee Y, Lee JH, Noh SH. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol. 2021;39:2903-2913.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 309]  [Cited by in RCA: 307]  [Article Influence: 61.4]  [Reference Citation Analysis (6)]
24.  Yu J, Gao Y, Chen L, Wu D, Shen Q, Zhao Z, Liu W, Yang H, Zhang Q, Wang X, Hu P, Zheng Z, Wang X, Liu H, Xu Z, Yan Z, Wu Y, Jin M, Zhang Q, Liu X, Zhu K, Shou C. Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2022;5:e220426.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 26]  [Cited by in RCA: 25]  [Article Influence: 6.3]  [Reference Citation Analysis (0)]
25.  Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ; CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389-1396.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 842]  [Cited by in RCA: 826]  [Article Influence: 68.8]  [Reference Citation Analysis (20)]
26.  Lai MY, Kang SY, Sun YT, Quan TT, Lu SX, He CY, Zhou ZW, Yang LQ, Luo HY, Wang FH, Li YH, Xu RH, Guan WL, Qiu MZ. Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systemic therapy of gastric cancer. BMC Cancer. 2022;22:1031.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 19]  [Cited by in RCA: 22]  [Article Influence: 5.5]  [Reference Citation Analysis (2)]
27.  Sun C, Niu P, Zhang X, Zhao L, Wang W, Luan X, Han X, Chen Y, Zhao D. Concurrent clinical and pathological response predicts favorable prognosis of patients with gastric cancer after neoadjuvant therapy: a real-world study. BMC Cancer. 2023;23:996.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 11]  [Reference Citation Analysis (1)]
Footnotes

Peer review: Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Gastroenterology and hepatology

Country of origin: China

Peer-review report’s classification

Scientific quality: Grade A, Grade C

Novelty: Grade A, Grade C

Creativity or innovation: Grade A, Grade C

Scientific significance: Grade A, Grade C

P-Reviewer: Guo KB, PhD, China; Li JT, MD, Assistant Professor, China S-Editor: Fan M L-Editor: A P-Editor: Wang WB

Write to the Help Desk